enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
3.370
-0.240 (-6.65%)
Nov 20, 2024, 4:00 PM EST - Market closed
enVVeno Medical Employees
enVVeno Medical had 31 employees as of December 31, 2023. The number of employees increased by 1 or 3.33% compared to the previous year.
Employees
31
Change (1Y)
1
Growth (1Y)
3.33%
Revenue / Employee
n/a
Profits / Employee
-$685,129
Market Cap
59.10M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Metagenomi | 236 |
Atara Biotherapeutics | 225 |
Hyperfine | 131 |
Celularity | 120 |
AlloVir | 112 |
X4 Pharmaceuticals | 93 |
Spero Therapeutics | 46 |
NVNO News
- 1 day ago - enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium - Accesswire
- 2 days ago - enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval - Accesswire
- 3 years ago - Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann - Accesswire
- 3 years ago - Hancock Jaffe To Rebrand As enVVeno Medical - Benzinga
- 3 years ago - Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs - Accesswire
- 3 years ago - Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021 - Accesswire
- 3 years ago - Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics - Seeking Alpha
- 3 years ago - Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules - Accesswire